A clinically applicable integrative molecular classification of meningiomas

Nassiri, Farshad; Liu, Jeff; Patil, Vikas; Mamatjan, Yasin; Wang, Justin Z; Hugh-White, Rupert; Macklin, Andrew; Khan, Shahbaz; Singh, Olivia; Karimi, Shirin; Corona, Rosario I.; Liu, Lydia; Chen, Caroline Y.; Chakravarthy, Ankur; Wei, Qingxia; Mehani, Bharati; Suppiah, Suganth; Gao, Andrew; Workewych, Adriana M.; Tabatabai, Ghazaleh; Boutros, Paul C.; Bader, Gary D.; Carvalho, Daniel D De; Kislinger, Thomas; Aldape, Kenneth; Zadeh, Gelareh

doi:10.1038/s41586-021-03850-3

Cited by 263 publications

(339 citation statements)

References 58 publications

Supporting

Mentioning

322

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, as discussed above, all of the recent developments are creating new prospects for effective molecularly driven diagnosis, classification and therapy of meningiomas (9)(10)(11). However, there is still a long way to go in the study of meningioma from many aspects.…”

Section: Discussionmentioning

confidence: 96%

Editorial: Meningioma: From Basic Research to Clinical Translational Study

Ho¹

2021

Front. Oncol.

View full text Add to dashboard Cite

Meningioma is thought to originate from arachnoidal cells in the central nervous system (CNS) and accounts for approximately 30% of all brain tumors (1). Most meningiomas are low grade benign brain tumors (such as fibroblastic meningioma and meningothelial meningioma), which belong to the World Health Organization (WHO) grade I and have a good prognosis after surgery. About 20% of meningiomas are high grade malignant brain tumors and belong to the WHO grade II (such as atypical meningioma) or WHO grade III (such as anaplastic meningioma) (2). Malignant meningiomas, sometimes may evolve from benign meningiomas, are more aggressive. They have an increased risk of recurrence after surgery and significant mortality rates. Currently, surgical resection combined with adjuvant radiotherapy is the main treatment strategy for malignant meningiomas, and no effective targeted chemotherapies have been developed (3-5).Thus, in this Research Topic (https://www.frontiersin.org/research-topics/12083/meningiomafrom-basic-research-to-clinical-translational-study), we collected more than 60 manuscripts discussing meningioma issues involving from basic research to clinical translational study, intend to deeply state those unresolved problems in meningioma. For example, its recurrence factors, how to improve the prognosis for malignant meningioma patients, what about the targeted chemotherapy for refractory meningioma? CLINICAL ASPECTS OF MENINGIOMAMeningiomas are diverse in intracranial locations and pathology, which are classified into three WHO grades and 15 histological subtypes. Sometimes meningiomas presented preferred intracranial locations, which may reflect potential biological features. In this meningioma issue collection, Sun et al. analyzed the preferred locations of meningioma according to different biological characteristics. Malignant meningiomas, compared to benign meningiomas, are more aggressive and have higher risk of recurrence after surgery. Clinical prognosis of meningioma patient is closely related to the WHO grades: patients with benign meningiomas have 5-year survival rates of 92%; however, the 5-year survival rates decrease to 78% in atypical meningiomas, and drop to 47% in anaplastic meningiomas. Currently, effective treatment for malignant meningiomas is still difficult (6). Here, we reviewed several manuscripts discussing meningioma treatment.

show abstract

Section: Discussionmentioning

confidence: 96%

Editorial: Meningioma: From Basic Research to Clinical Translational Study

Ho¹

2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Each molecular group showed distinctive and prototypical biology (immunogenic, benign NF2 wild-type, hypermetabolic and proliferative) that informed therapeutic options. Proteogenomic characterization reinforced the robustness of defined molecular groups and uncovered highly abundant and group-specific protein targets [26].…”

Section: Cytogenetics and Genomicsmentioning

confidence: 97%

“…Additionally, a study showed that the levels of p16 and p15, the proteins encoded by CDKN2A and CDKN2B, may hold prognostic significance and/ or represent a promising therapeutic target [25]. Recently, Nassiri et al described four consensus molecular groups of MN by combining DNA somatic copy-number aberrations, DNA somatic point mutations, DNA methylation, and messenger RNA abundance in a unified analysis [26]. These molecular groups predicted clinical outcomes compared with existing classification schemes.…”

Section: Cytogenetics and Genomicsmentioning

confidence: 99%

High Grade Meningiomas: Current Therapy Based on Tumor Biology

García-Robledo¹,

Ordóñez-Reyes²,

Ruíz-Patiño³

et al. 2022

Brain Tumors

View full text Add to dashboard Cite

Atypical (WHO grade II) and malignant meningiomas (WHO Grade III) are a rare subset of primary intracranial tumors. Due to the high recurrence rate after surgical resection and radiotherapy, there has been a recent interest in exploring other systemic treatment options for these refractory tumors. Recent advances in molecular sequencing of tumors have elucidated new pathways and drug targets currently being studied. This article provides a thorough overview of novel investigational therapeutics, including targeted therapy, immunotherapy, and new technological modalities for atypical and malignant meningiomas. There is encouraging preclinical evidence regarding the efficacy of the emerging treatments discussed in this chapter. Several clinical trials are currently recruiting patients to translate targeted molecular therapy for recurrent and high-grade meningiomas.

show abstract

“…Most studies have focused on diagnosis in the context of CNS tumors where tissue acquisition is challenging or impossible such as pediatric posterior fossa tumors [19], rare histologies or histologies that present difficult diagnostic interpretation (ependymoma, pilocytic astrocytoma, medulloblastoma, craniopharyngioma) [10,20,27,78,79] and very few studies examined computational avenues to optimise RT [80], Zhu [81]. In meningioma attempts have focused on diagnosis and grading especially in the context of radiomics and surgical resection [21] and linked analysis to extent of tumor and brain or bone invasion [82][83][84][85]. If analysed in conjunction with biomarkers and RT dosimetry, these endeavors could prove highly relevant to RT volumes and dose as well patterns of recurrence [86][87][88] but clinical applications are only starting to emerge [89].…”

Section: Radiogenomic Advances In Rare Cns Histologies Craniospinal A...mentioning

confidence: 99%

Molecular Biology in Treatment Decision Processes—Neuro-Oncology Edition

Krauze

Camphausen

2021

IJMS

View full text Add to dashboard Cite

Computational approaches including machine learning, deep learning, and artificial intelligence are growing in importance in all medical specialties as large data repositories are increasingly being optimised. Radiation oncology as a discipline is at the forefront of large-scale data acquisition and well positioned towards both the production and analysis of large-scale oncologic data with the potential for clinically driven endpoints and advancement of patient outcomes. Neuro-oncology is comprised of malignancies that often carry poor prognosis and significant neurological sequelae. The analysis of radiation therapy mediated treatment and the potential for computationally mediated analyses may lead to more precise therapy by employing large scale data. We analysed the state of the literature pertaining to large scale data, computational analysis, and the advancement of molecular biomarkers in neuro-oncology with emphasis on radiation oncology. We aimed to connect existing and evolving approaches to realistic avenues for clinical implementation focusing on low grade gliomas (LGG), high grade gliomas (HGG), management of the elderly patient with HGG, rare central nervous system tumors, craniospinal irradiation, and re-irradiation to examine how computational analysis and molecular science may synergistically drive advances in personalised radiation therapy (RT) and optimise patient outcomes.

show abstract

A clinically applicable integrative molecular classification of meningiomas

Cited by 263 publications

References 58 publications

Editorial: Meningioma: From Basic Research to Clinical Translational Study

Editorial: Meningioma: From Basic Research to Clinical Translational Study

High Grade Meningiomas: Current Therapy Based on Tumor Biology

Molecular Biology in Treatment Decision Processes—Neuro-Oncology Edition

Contact Info

Product

Resources

About